Serge Leyvraz

Lausanne, VD, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Author Correction: Base-excision repair pathway shapes 5-methylcytosine deamination signatures in pan-cancer genomes.

Author Correction: Base-excision repair pathway shapes 5-methylcytosine deamination signatures in pan-cancer genomes.

Journal: Nature communications

Published: July 02, 2025

Sorafenib plus selective internal radiotherapy with 90Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial.

Sorafenib plus selective internal radiotherapy with 90Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial.

Journal: British journal of cancer

Published: April 06, 2025

Direct genetic transformation bypasses tumor-associated DNA methylation alterations.

Direct genetic transformation bypasses tumor-associated DNA methylation alterations.

Journal: Genome biology

Published: October 15, 2024

Characterizing uveal melanoma patients with peritoneal metastases: A retrospective single-center analysis.

Characterizing uveal melanoma patients with peritoneal metastases: A retrospective single-center analysis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 02, 2024

Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.

Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.

Journal: Journal for immunotherapy of cancer

Published: April 19, 2024

A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass.

A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass.

Journal: The oncologist

Published: March 21, 2024

Base-excision repair pathway shapes 5-methylcytosine deamination signatures in pan-cancer genomes.

Base-excision repair pathway shapes 5-methylcytosine deamination signatures in pan-cancer genomes.

Journal: Nature communications

Published: January 22, 2024

A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.

A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 22, 2023

A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.

A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.

Journal: Cancer research communications

Published: August 03, 2023

Tumour mutational burden and survival with molecularly matched therapy.

Tumour mutational burden and survival with molecularly matched therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 27, 2023

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.

Journal: Cancer

Published: March 02, 2023

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.

Journal: Nature medicine

Published: April 04, 2022

Showing 1-12 of 52

Last Updated: 09/26/2026